System Optimization for In Situ Fiber-Optic Dissolution Testing: Hydrodynamic Effects, System Performance, and Applications

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2001
Volume 25
Issue 10

Testing of an in situ fiber-optic transmission probe demonstrates sound hydrodynamic performance and reduced stray-light limitations.

External Link - article-4492.pdf

Articles in this issue
Outsourcing Outlook
Effects of Polyethylene Glycol on Morphology, Thermomechanical Properties, and Water Vapor Permeability of Cellulose Acetate-Free Films
Hydrogels for the Controlled Release of Pharmaceutical Proteins
Near-Infrared Inspection Complements Other QC Systems
Safety and Manufacturing Standards
System Optimization for In Situ Fiber-Optic Dissolution Testing: Hydrodynamic Effects, System Performance, and Applications
Current Status of the Oral Delivery of Insulin
Laboratory Equipment Qualification
Filter Integrity Testing in Liquid Applications, Revisited, Part I
360&#176 Feedback &#45 Improving the Selection Process All the Way Around
Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Beckman Coulter Life Sciences Launches Modular Spectral Flow Cytometry Module, First of Its Kind in Industry

Feliza Mirasol
March 28th 2025
Article

The CytoFLEX mosaic Spectral Detection Module offers up to 88 channels for detection.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Sherwin-Williams to Showcase Next-Gen Coatings for Pharma Cleanrooms at INTERPHEX 2025

Feliza Mirasol
March 28th 2025
Article

Sherwin-Williams’ advanced coating systems are designed to ensure safety, sterility, and efficiency in pharma manufacturing environments.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations

Feliza Mirasol
March 27th 2025
Article

In the latest of a series of warning letters to India-based API manufacturers, FDA issued a warning letter to Aspen for deviations in CGMP in the production of APIs.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

BIO Survey: Tariffs May Reduce Access, Delay Innovation, Create Red Tape

Patrick Lavery
March 27th 2025
Article

The Biotechnology Innovation Organization’s new membership survey said that 90% of US biotech companies rely on imported components for at least half of their FDA-approved products.